company background image
ORCHPHARMA logo

Orchid Pharma NSEI:ORCHPHARMA Stock Report

Last Price

₹1.38k

Market Cap

₹70.2b

7D

20.7%

1Y

145.1%

Updated

23 Jul, 2024

Data

Company Financials +

Orchid Pharma Limited

NSEI:ORCHPHARMA Stock Report

Market Cap: ₹70.2b

ORCHPHARMA Stock Overview

A pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.

ORCHPHARMA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for ORCHPHARMA from our risk checks.

Orchid Pharma Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orchid Pharma
Historical stock prices
Current Share Price₹1,375.90
52 Week High₹1,425.00
52 Week Low₹432.05
Beta2.35
11 Month Change17.69%
3 Month Change29.19%
1 Year Change145.08%
33 Year Change187.03%
5 Year Changen/a
Change since IPO7,543.89%

Recent News & Updates

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12
We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Recent updates

We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Jun 12
We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease

Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

May 08
Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price

Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Feb 28
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce

Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Feb 06
Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?

Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Dec 18
Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump

Shareholder Returns

ORCHPHARMAIN PharmaceuticalsIN Market
7D20.7%-0.6%-1.5%
1Y145.1%47.4%43.8%

Return vs Industry: ORCHPHARMA exceeded the Indian Pharmaceuticals industry which returned 47.4% over the past year.

Return vs Market: ORCHPHARMA exceeded the Indian Market which returned 43.8% over the past year.

Price Volatility

Is ORCHPHARMA's price volatile compared to industry and market?
ORCHPHARMA volatility
ORCHPHARMA Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.2%

Stable Share Price: ORCHPHARMA's share price has been volatile over the past 3 months.

Volatility Over Time: ORCHPHARMA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992838Manish Dhanukawww.orchidpharma.com

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company’s multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services.

Orchid Pharma Limited Fundamentals Summary

How do Orchid Pharma's earnings and revenue compare to its market cap?
ORCHPHARMA fundamental statistics
Market cap₹70.17b
Earnings (TTM)₹921.67m
Revenue (TTM)₹8.19b

75.7x

P/E Ratio

8.5x

P/S Ratio

Is ORCHPHARMA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ORCHPHARMA income statement (TTM)
Revenue₹8.19b
Cost of Revenue₹4.84b
Gross Profit₹3.35b
Other Expenses₹2.43b
Earnings₹921.67m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)18.17
Gross Margin40.87%
Net Profit Margin11.25%
Debt/Equity Ratio11.5%

How did ORCHPHARMA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.